- Home
- RMCF vs PTN Comparison
RMCF vs PTN Comparison
Compare RMCF & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- PTN
- Stock Information
- Founded
- RMCF 1981
- PTN 1986
- Country
- RMCF United States
- PTN United States
- Employees
- RMCF N/A
- PTN N/A
- Industry
- RMCF Specialty Foods
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- PTN Health Care
- Exchange
- RMCF Nasdaq
- PTN Nasdaq
- Market Cap
- RMCF 21.3M
- PTN 25.4M
- IPO Year
- RMCF N/A
- PTN 1993
- Fundamental
- Price
- RMCF $1.85
- PTN $0.83
- Analyst Decision
- RMCF
- PTN Strong Buy
- Analyst Count
- RMCF 0
- PTN 1
- Target Price
- RMCF N/A
- PTN $17.00
- AVG Volume (30 Days)
- RMCF 30.3K
- PTN 389.9K
- Earning Date
- RMCF 01-14-2025
- PTN 02-13-2025
- Dividend Yield
- RMCF N/A
- PTN N/A
- EPS Growth
- RMCF N/A
- PTN N/A
- EPS
- RMCF N/A
- PTN N/A
- Revenue
- RMCF $27,939,687.00
- PTN $2,384,113.00
- Revenue This Year
- RMCF N/A
- PTN N/A
- Revenue Next Year
- RMCF N/A
- PTN N/A
- P/E Ratio
- RMCF N/A
- PTN N/A
- Revenue Growth
- RMCF N/A
- PTN N/A
- 52 Week Low
- RMCF $1.50
- PTN $0.68
- 52 Week High
- RMCF $4.53
- PTN $4.65
- Technical
- Relative Strength Index (RSI)
- RMCF 33.42
- PTN 35.48
- Support Level
- RMCF $1.77
- PTN $0.79
- Resistance Level
- RMCF $1.94
- PTN $0.97
- Average True Range (ATR)
- RMCF 0.11
- PTN 0.08
- MACD
- RMCF -0.01
- PTN -0.02
- Stochastic Oscillator
- RMCF 17.02
- PTN 8.57
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.